Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Solid Malignancies × Fulvestrant × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 45 Ovarian Neoplasms 6 Neoplasm Metastasis 6 Carcinoma, Non-Small-Cell Lung 6 Neoplasms 5 Triple Negative Breast Neoplasms 4 Advanced Breast Cancer 4 Prostatic Neoplasms 3 Endometrial Neoplasms 3 Stomach Neoplasms 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Colorectal Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Solid Tumor 1 Solid Malignancies 1 Small Cell Lung Carcinoma 1 Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1 Neoplasms by Site 1 Mesothelioma, Malignant 1 Mesothelioma 1 Lung Neoplasms 1 Liposarcoma 1 Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1 Hereditary Sensory and Autonomic Neuropathies 1 HR Positive/HER-2 Negative Breast Cancer 1

Interventions

tremelimumab 1 ixabepilone 1 durvalumab 1 ST 1481 1 Paclitaxel 1 Fulvestrant 1 Docetaxel 1 Axitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02640755 2019-04-22

14C

AstraZeneca

Phase 1 Completed

4 enrolled 34 charts

Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon ⚡